

# Sultan Darvesh

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2337829/publications.pdf>

Version: 2024-02-01

126  
papers

6,602  
citations

117625

34  
h-index

66911

78  
g-index

155  
all docs

155  
docs citations

155  
times ranked

7181  
citing authors

#	ARTICLE	IF	CITATIONS
1	Distribution of acetylcholinesterase in the hippocampal formation of the Atlantic white-sided dolphin ( <i>Lagenorhynchus acutus</i> ). <i>Journal of Comparative Neurology</i> , 2021, 529, 1029-1051.	1.6	0
2	Imaging Butyrylcholinesterase in Multiple Sclerosis. <i>Molecular Imaging and Biology</i> , 2021, 23, 127-138.	2.6	8
3	2-Pyridone natural products as inhibitors of SARS-CoV-2 main protease. <i>Chemico-Biological Interactions</i> , 2021, 335, 109348.	4.0	35
4	Clinical and neuropathological variability in the rare IVS10+ 14 tau mutation. <i>Neurobiology of Aging</i> , 2021, 101, 298.e1-298.e10.	3.1	1
5	Clinicopathological correlations and cholinesterase expression in early-onset familial Alzheimer's disease with the presenilin 1 mutation, Leu235Pro. <i>Neurobiology of Aging</i> , 2021, 103, 31-41.	3.1	2
6	Mild Microglial Responses in the Cortex and Perivascular Macrophage Infiltration in Subcortical White Matter in Dogs with Age-Related Dementia Modelling Prodromal Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 82, 575-592.	2.6	3
7	Interaction of Exogenous Butyrylcholinesterase with $\beta$ -Amyloid Plaques in 5XFAD/Butyrylcholinesterase-Knockout Mouse Brain. <i>Current Alzheimer Research</i> , 2021, 18, 470-481.	1.4	3
8	Phenothiazines as dual inhibitors of SARS-CoV-2 main protease and COVID-19 inflammation. <i>Canadian Journal of Chemistry</i> , 2021, 99, 801-811.	1.1	4
9	Neuropathologic burden and the degree of frailty in relation to global cognition and dementia. <i>Neurology</i> , 2020, 95, e3269-e3279.	1.1	33
10	1-(3-Tert-Butylphenyl)-2,2,2-Trifluoroethanone as a Potent Transition-State Analogue Slow-Binding Inhibitor of Human Acetylcholinesterase: Kinetic, MD and QM/MM Studies. <i>Biomolecules</i> , 2020, 10, 1608.	4.0	8
11	Intact olfactory memory in the 5xFAD mouse model of Alzheimer's disease from 3 to 15 months of age. <i>Behavioural Brain Research</i> , 2020, 393, 112731.	2.2	19
12	Butyrylcholinesterase as a biomarker in Alzheimer's disease. , 2020, , 263-280.		1
13	Clock Drawing Test in acute stroke and its relationship with long-term functional and cognitive outcomes. <i>Clinical Neuropsychologist</i> , 2019, 33, 817-830.	2.3	12
14	Ageing and amyloidosis underlie the molecular and pathological alterations of tau in a mouse model of familial Alzheimer's disease. <i>Scientific Reports</i> , 2019, 9, 15758.	3.3	27
15	Cholinergic Neurons in Nucleus Subputaminalis in Primary Progressive Aphasia. <i>Canadian Journal of Neurological Sciences</i> , 2019, 46, 174-183.	0.5	4
16	ICP-136: SYNTHESIS AND <i>IN VIVO</i> BRAIN PET EVALUATION OF 1-METHYL-4-PIPERIDYL [F]FLOUROBENZOATE (TRV6501): A BUTYRYLCHOLINESTERASE-SPECIFIC RADIOLIGAND FOR ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, P112.	0.5	0
17	A.03 Cholinergic Neurons in Nucleus Subputaminalis in Primary Progressive Aphasia. <i>Canadian Journal of Neurological Sciences</i> , 2019, 46, S8.	0.5	0
18	Increased Inflammation and Unchanged Density of Synaptic Vesicle Glycoprotein 2A (SV2A) in the Postmortem Frontal Cortex of Alzheimer's Disease Patients. <i>Frontiers in Cellular Neuroscience</i> , 2019, 13, 538.	3.7	25

#	ARTICLE	IF	CITATIONS
19	Evidence for Cholinergic Dysfunction in Autosomal Dominant Kufs Disease. Canadian Journal of Neurological Sciences, 2018, 45, 150-157.	0.5	10
20	The cholinergic system in the basal forebrain of the Atlantic white-sided dolphin ( <i>Lagenorhynchus tjedti</i> ). <i>Journal of Neurocytology</i> , 2018, 47, 100-110.	1.6	1
21	ICP1065: BUTYRYLCHOLINESTERASE GENETIC POLYMORPHISM AND NEUROIMAGING BIOMARKERS IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P59.	0.8	0
22	P1424: BUTYRYLCHOLINESTERASE GENETIC POLYMORPHISM AND NEUROIMAGING BIOMARKERS IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P468.	0.8	0
23	Diverse Protein Profiles in CNS Myeloid Cells and CNS Tissue From Lipopolysaccharide- and Vehicle-Injected APPSWE/PS1 <sup>E9</sup> Transgenic Mice Implicate Cathepsin Z in Alzheimer's Disease. <i>Frontiers in Cellular Neuroscience</i> , 2018, 12, 397.	3.7	26
24	The Toronto Cognitive Assessment (TorCA): normative data and validation to detect amnesic mild cognitive impairment. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 65.	6.2	30
25	Reduced Serotonin Transporter Levels and Inflammation in the Midbrain Raphe of 12 Month Old APP <sup>swe</sup> /PSEN1 <sup>dE9</sup> Mice. <i>Current Alzheimer Research</i> , 2018, 15, 420-428.	1.4	10
26	Targeting butyrylcholinesterase for preclinical single photon emission computed tomography (SPECT) imaging of Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 166-176.	3.7	19
27	Butyrylcholinesterase-knockout reduces fibrillar $\beta$ -amyloid and conserves 18FDG retention in 5XFAD mouse model of Alzheimer's disease. <i>Brain Research</i> , 2017, 1671, 102-110.	2.2	27
28	Cholinesterases in normal and Alzheimer's disease primary olfactory gyrus. <i>Neuropathology and Applied Neurobiology</i> , 2017, 43, 571-583.	3.2	7
29	Quantification of Butyrylcholinesterase Activity as a Sensitive and Specific Biomarker of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 491-505.	2.6	57
30	[P3190]: ALZHEIMER PATHOLOGY AND CHOLINESTERASES IN THE PRIMARY OLFACTORY GYRUS. <i>Alzheimer's and Dementia</i> , 2017, 13, P1007.	0.8	0
31	[ICP023]: CEREBRAL PERFUSION IN THE 5XFAD MOUSE MODEL OF ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P24.	0.8	0
32	[P1353]: CEREBRAL PERFUSION IN THE 5XFAD MOUSE MODEL OF ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P393.	0.8	0
33	Comparison of the Binding of Reversible Inhibitors to Human Butyrylcholinesterase and Acetylcholinesterase: A Crystallographic, Kinetic and Calorimetric Study. <i>Molecules</i> , 2017, 22, 2098.	3.8	179
34	ICP163: Synthesis and <i>In Vivo</i> Spect Evaluation of a Novel Butyrylcholinesterase Diagnostic Radioligand for Alzheimer's Disease. <i>Alzheimer's and Dementia</i> , 2016, 12, P120.	0.8	1
35	P3-261: Synthesis and <i>IN VIVO</i> Spect Evaluation of a Novel Butyrylcholinesterase Diagnostic Radioligand for Alzheimer's Disease. , 2016, 12, P932-P932.		0
36	Reduced fibrillar $\beta$ -amyloid in subcortical structures in a butyrylcholinesterase-knockout Alzheimer disease mouse model. <i>Chemico-Biological Interactions</i> , 2016, 259, 307-312.	4.0	43

#	ARTICLE	IF	CITATIONS
37	Development of acetophenone ligands as potential neuroimaging agents for cholinesterases. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 5270-5279.	3.0	6
38	Synthesis and Preliminary Evaluation of Phenyl 4- <sup>123</sup> I-Iodophenylcarbamate for Visualization of Cholinesterases Associated with Alzheimer Disease Pathology. <i>Journal of Nuclear Medicine</i> , 2016, 57, 297-302.	5.0	12
39	An integrated proteomics approach shows synaptic plasticity changes in an APP/PS1 Alzheimer's mouse model. <i>Oncotarget</i> , 2016, 7, 33627-33648.	1.8	55
40	Butyrylcholinesterase as a Diagnostic and Therapeutic Target for Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2016, 13, 1173-1177.	1.4	126
41	IC-P-022: Cerebral glucose metabolism in a 5XFAD butyrylcholinesterase-knockout mouse model of Alzheimer's disease. , 2015, 11, P25-P26.		0
42	P1-160: Cerebral glucose metabolism in a 5XFAD butyrylcholinesterase-knockout mouse model of Alzheimer's disease. , 2015, 11, P406-P406.		0
43	Butyrylcholinesterase-knockout reduces brain deposition of fibrillar $\beta$ -amyloid in an Alzheimer mouse model. <i>Neuroscience</i> , 2015, 298, 424-435.	2.3	109
44	P1-030: Butyrylcholinesterase knockout reduces deposition of fibrillar $\beta$ -amyloid in an Alzheimer's mouse model. , 2015, 11, P348-P348.		0
45	P1-210: Comparison of butyrylcholinesterase and $\beta$ -amyloid as diagnostic markers for the definitive diagnosis of Alzheimer's disease. , 2015, 11, P431-P431.		1
46	Early Detection of Cerebral Glucose Uptake Changes in the 5XFAD Mouse. <i>Current Alzheimer Research</i> , 2014, 11, 450-460.	1.4	64
47	P1-261: CHANGES IN PREFRONTAL ACTIVATION IN EARLY ALZHEIMER'S DISEASE: A MAGNETOENCEPHALOGRAPHY (MEG) STUDY. , 2014, 10, P403-P404.		1
48	Peripheral Dysgraphia. <i>Cognitive and Behavioral Neurology</i> , 2014, 27, 31-47.	0.9	3
49	Cholinesterase Inhibition in Alzheimer's Disease: Is Specificity the Answer?. <i>Journal of Alzheimer's Disease</i> , 2014, 42, 379-384.	2.6	68
50	P1-311: CLINICOPATHOLOGICAL CORRELATION OF NEURODEGENERATIVE CASES IN A DEMENTIA UNIT. , 2014, 10, P425-P426.		0
51	IC-P-098: ALTERNATIVE CEREBRAL GLUCOSE UPTAKE METRICS DETECT EARLY METABOLIC CHANGES IN THE 5XFAD MOUSE MODEL OF ALZHEIMER'S DISEASE. , 2014, 10, P55-P55.		0
52	P1-296: ALTERNATIVE CEREBRAL GLUCOSE UPTAKE METRICS DETECT EARLY METABOLIC CHANGES IN THE 5XFAD MOUSE MODEL OF ALZHEIMER'S DISEASE. , 2014, 10, P419-P419.		0
53	Thioesters for the in vitro evaluation of agents to image brain cholinesterases. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2013, 28, 447-455.	5.2	3
54	Butyrylcholinesterase and the cholinergic system. <i>Neuroscience</i> , 2013, 234, 53-68.	2.3	80

#	ARTICLE	IF	CITATIONS
55	Butyrylcholinesterase radioligands to image Alzheimer's disease brain. <i>Chemico-Biological Interactions</i> , 2013, 203, 354-357.	4.0	18
56	Selectivity of phenothiazine cholinesterase inhibitors for neurotransmitter systems. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 3822-3825.	2.2	15
57	Butyrylcholinesterase Is Associated With $\beta$ -Amyloid Plaques in the Transgenic APP <sup>SWE</sup> /PSEN1 <sup>dE9</sup> Mouse Model of Alzheimer Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2012, 71, 2-14.	1.7	114
58	Probing the Peripheral Site of Human Butyrylcholinesterase. <i>Biochemistry</i> , 2012, 51, 7046-7053.	2.5	50
59	Information Processing and Magnetic Resonance Imaging Indices of Brain Pathology in Multiple Sclerosis. <i>International Journal of MS Care</i> , 2012, 14, 84-91.	1.0	7
60	Cysteine Thioesters as Myelin Proteolipid Protein Analogues to Examine the Role of Butyrylcholinesterase in Myelin Decompaction. <i>ACS Chemical Neuroscience</i> , 2011, 2, 151-159.	3.5	11
61	An MRI Brain Atrophy and Lesion Index to Assess the Progression of Structural Changes in Alzheimer's Disease, Mild Cognitive Impairment, and Normal Aging: A Follow-Up Study. <i>Journal of Alzheimer's Disease</i> , 2011, 26, 359-367.	2.6	30
62	Limitations of conventional inhibitor classifications. <i>Integrative Biology (United Kingdom)</i> , 2011, 3, 1197.	1.3	14
63	Potentially Procholinergic Effects of Medications Commonly Used in Older Adults. <i>American Journal of Geriatric Pharmacotherapy</i> , 2011, 9, 80-87.	3.0	8
64	Synergistic inhibition of butyrylcholinesterase by galantamine and citalopram. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2011, 1810, 1230-1235.	2.4	21
65	Synthesis and Preliminary Evaluation of Piperidinyl and Pyrrolidinyl Iodobenzoates as Imaging Agents for Butyrylcholinesterase. <i>Molecular Imaging and Biology</i> , 2011, 13, 1250-1261.	2.6	8
66	Differential binding of phenothiazine urea derivatives to wild-type human cholinesterases and butyrylcholinesterase mutants. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 2232-2244.	3.0	34
67	Butyrylcholinesterase activity in multiple sclerosis neuropathology. <i>Chemico-Biological Interactions</i> , 2010, 187, 425-431.	4.0	37
68	An MRI-Based Semiquantitative Index for the Evaluation of Brain Atrophy and Lesions in Alzheimer's Disease, Mild Cognitive Impairment and Normal Aging. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010, 30, 121-130.	1.5	26
69	Biochemical and Histochemical Comparison of Cholinesterases in Normal and Alzheimer Brain Tissues. <i>Current Alzheimer Research</i> , 2010, 7, 386-400.	1.4	35
70	A method to describe enzyme-catalyzed reactions by combining steady state and time course enzyme kinetic parameters. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2010, 1800, 1-5.	2.4	29
71	Donepezil delays progression to AD in MCI subjects with depressive symptoms. <i>Neurology</i> , 2009, 72, 2115-2121.	1.1	129
72	Carbamates with Differential Mechanism of Inhibition Toward Acetylcholinesterase and Butyrylcholinesterase. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 4200-4212.	6.4	136

#	ARTICLE	IF	CITATIONS
73	Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI. <i>Neurobiology of Aging</i> , 2008, 29, 1285-1295.	3.1	138
74	Lipid-Lowering Agents and the Risk of Cognitive Impairment That Does Not Meet Criteria for Dementia, in Relation to Apolipoprotein E Status. <i>Neuroepidemiology</i> , 2007, 29, 201-207.	2.3	14
75	A versatile equation to describe reversible enzyme inhibition and activation kinetics: Modeling $\beta$ -galactosidase and butyrylcholinesterase. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2007, 1770, 733-746.	2.4	24
76	A medical health report on individuals with silent butyrylcholinesterase in the Vysya community of India. <i>Clinica Chimica Acta</i> , 2007, 378, 128-135.	1.1	95
77	Human serum cholinesterase from liver pathological samples exhibit highly elevated aryl acylamidase activity. <i>Clinica Chimica Acta</i> , 2007, 380, 151-156.	1.1	15
78	Progressive Anomia Without Semantic or Phonological Impairment. <i>Cortex</i> , 2007, 43, 558-564.	2.4	7
79	Aryl acylamidase activity of human serum albumin with <i>o</i> -nitrotrifluoroacetanilide as the substrate. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2007, 22, 463-469.	5.2	29
80	Sensitivity of butyrylcholinesterase knockout mice to ( $\alpha$ )-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission. <i>Toxicology</i> , 2007, 233, 60-69.	4.2	85
81	Kinetic analysis of butyrylcholinesterase-catalyzed hydrolysis of acetanilides. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2007, 1774, 1139-1147.	2.3	26
82	Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine. <i>Bioorganic and Medicinal Chemistry</i> , 2007, 15, 6367-6378.	3.0	52
83	Homocysteine Thiolactone and Human Cholinesterases. <i>Cellular and Molecular Neurobiology</i> , 2007, 27, 33-48.	3.3	20
84	Comparison of cognitive functions between people with silent and wild-type butyrylcholinesterase. <i>Journal of Neural Transmission</i> , 2007, 114, 939-945.	2.8	18
85	Improved prediction of early-onset coronary artery disease using APOE $\epsilon$ 4, BChE-K, PPAR $\gamma$ 2 Pro12 and ENOS T-786C in a polygenic model. <i>Clinical Biochemistry</i> , 2006, 39, 109-114.	1.9	30
86	On the active site for hydrolysis of aryl amides and choline esters by human cholinesterases. <i>Bioorganic and Medicinal Chemistry</i> , 2006, 14, 4586-4599.	3.0	41
87	Tomographic visualization of cholinesterase. <i>Annals of Neurology</i> , 2006, 60, 745-746.	5.3	1
88	The Behavioural Neurology Assessment. <i>Canadian Journal of Neurological Sciences</i> , 2005, 32, 167-177.	0.5	48
89	Structure-activity relationships for inhibition of human cholinesterases by alkyl amide phenothiazine derivatives. <i>Bioorganic and Medicinal Chemistry</i> , 2005, 13, 211-222.	3.0	55
90	Cholinesterases: Roles in the Brain During Health and Disease. <i>Current Alzheimer Research</i> , 2005, 2, 307-318.	1.4	303

#	ARTICLE	IF	CITATIONS
91	Disconnection of Language and Memory in Semantic Dementia: A Comparative and Theoretical Analysis. <i>Current Alzheimer Research</i> , 2005, 2, 435-448.	1.4	1
92	Corticobasal Degeneration Substantiated by Imaging Studies. <i>American Journal of Geriatric Psychiatry</i> , 2005, 13, 333-334.	1.2	2
93	Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment. <i>New England Journal of Medicine</i> , 2005, 352, 2379-2388.	27.0	1,709
94	Corticobasal Degeneration Substantiated by Imaging Studies. <i>American Journal of Geriatric Psychiatry</i> , 2005, 13, 333-334.	1.2	1
95	Differential effects of lipid-lowering agents on human cholinesterases. <i>Clinical Biochemistry</i> , 2004, 37, 42-49.	1.9	32
96	P3-178 Butyrylcholinesterase activity in the human amygdala, hippocampal formation and the thalamus in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2004, 25, S406.	3.1	1
97	Cholinesterase inhibitors modify the activity of intrinsic cardiac neurons. <i>Experimental Neurology</i> , 2004, 188, 461-470.	4.1	14
98	S2-02-05 Use of lipid lowering agents and the risk of cognitive impairment, not dementia in relation to apolipoprotein E status. <i>Neurobiology of Aging</i> , 2004, 25, S27.	3.1	1
99	Butyrylcholinesterase, cholinergic neurotransmission and the pathology of Alzheimer's disease. <i>Drugs of Today</i> , 2004, 40, 711.	2.4	67
100	Hippocampal Volume Is Associated with Memory but not Nonmemory Cognitive Performance in Patients with Mild Cognitive Impairment. <i>Journal of Molecular Neuroscience</i> , 2003, 20, 241-248.	2.3	67
101	Enantiomer effects of huperzine A on the aryl acylamidase activity of human cholinesterases. <i>Cellular and Molecular Neurobiology</i> , 2003, 23, 93-100.	3.3	9
102	Differential distribution of butyrylcholinesterase and acetylcholinesterase in the human thalamus. <i>Journal of Comparative Neurology</i> , 2003, 463, 25-43.	1.6	115
103	Neurobiology of butyrylcholinesterase. <i>Nature Reviews Neuroscience</i> , 2003, 4, 131-138.	10.2	719
104	The risk of dementia in relation to statins and other lipid lowering agents. <i>Neurological Research</i> , 2003, 25, 601-604.	1.3	24
105	Inhibition of Human Cholinesterases by Drugs Used to Treat Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2003, 17, 117-126.	1.3	134
106	Simultaneous intrastriatal and intranigral fetal dopaminergic grafts in patients with Parkinson disease: a pilot study. <i>Journal of Neurosurgery</i> , 2002, 96, 589-596.	1.6	145
107	Relation between butyrylcholinesterase K variant, paraoxonase 1 (PON1) Q and R and apolipoprotein E $\epsilon$ 4 genes in early-onset coronary artery disease. <i>Clinical Biochemistry</i> , 2002, 35, 205-209.	1.9	20
108	Alzheimer's Disease and Related Disorders Annual. 2000. Edited by Serge Gauthier, and Jeffery L. Cummings. Published by Martin Dunitz Ltd. 255 pages. C\$102.00 approx.. <i>Canadian Journal of Neurological Sciences</i> , 2001, 28, 379-379.	0.5	1



#	ARTICLE	IF	CITATIONS
109	Butyrylcholinesterase and Cognitive Function. <i>International Psychogeriatrics</i> , 2001, 13, 461-464.	1.0	30
110	Estimating the Prevalence of Dementia in Elderly People: A Comparison of the Canadian Study of Health and Aging and National Population Health Survey Approaches. <i>International Psychogeriatrics</i> , 2001, 13, 169-175.	1.0	57
111	Butyrylcholinesterase-Mediated enhancement of the enzymatic activity of trypsin. <i>Cellular and Molecular Neurobiology</i> , 2001, 21, 285-296.	3.3	27
112	Inter-Rater Reliability of the Diagnosis of Vascular Cognitive Impairment at a Memory Clinic. <i>Neuroepidemiology</i> , 2000, 19, 186-193.	2.3	30
113	Enhancement of survival of stored dopaminergic cells and promotion of graft survival by exposure of human fetal nigral tissue to glial cell line-derived neurotrophic factor in patients with Parkinson's disease. <i>Journal of Neurosurgery</i> , 2000, 92, 863-869.	1.6	106
114	Spectrum of Disease in Vascular Cognitive Impairment. <i>Neuroepidemiology</i> , 1999, 18, 248-254.	2.3	90
115	Distribution of butyrylcholinesterase in the human amygdala and hippocampal formation. , 1998, 393, 374-390.		127
116	Cholinesterases in cardiac ganglia and modulation of canine intrinsic cardiac neuronal activity. <i>Journal of the Autonomic Nervous System</i> , 1998, 71, 75-84.	1.9	22
117	Retrospective Diagnosis of Dementia Using an Informant Interview Based on the Brief Cognitive Rating Scale. <i>International Psychogeriatrics</i> , 1998, 10, 53-60.	1.0	30
118	Distribution of butyrylcholinesterase in the human amygdala and hippocampal formation. <i>Journal of Comparative Neurology</i> , 1998, 393, 374-90.	1.6	42
119	Subcortical Dementia: A Neurobehavioral Approach. <i>Brain and Cognition</i> , 1996, 31, 230-249.	1.8	35
120	Synthetic studies towards bruceantin. Part 2. The synthesis of a pentacyclic intermediate. <i>Canadian Journal of Chemistry</i> , 1991, 69, 723-731.	1.1	7
121	Synthetic studies towards bruceantin. Part 1. Establishment of the carbon network. <i>Canadian Journal of Chemistry</i> , 1991, 69, 712-722.	1.1	13
122	An approach to the synthesis of bruceantin. The synthesis of a tetracyclic intermediate. <i>Canadian Journal of Chemistry</i> , 1989, 67, 2237-2240.	1.1	17
123	Distribution of neuropeptide-like immunoreactivity in intact and chronically decentralized middle cervical and stellate ganglia of dogs. <i>Journal of the Autonomic Nervous System</i> , 1987, 21, 167-180.	1.9	38
124	Electroantennograms and Trapping with Spruce Budworm (Lepidoptera: Tortricidae) Sex Pheromone Analogues. <i>Environmental Entomology</i> , 1982, 11, 1285-1289.	1.4	2
125	Spruce budworm: Roles of pheromone components and analogues in male disruption and attraction. <i>Experientia</i> , 1980, 36, 222-223.	1.2	9
126	EFFECTS OF PHEROMONE, PHEROMONE COMPONENTS, AND PHEROMONE ANALOGUES ON MATING OF THE SPRUCE BUDWORM (LEPIDOPTERA: TORTRICIDAE). <i>Canadian Entomologist</i> , 1980, 112, 605-608.	0.8	5